Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis.


Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
11 2021
Historique:
pubmed: 17 2 2021
medline: 28 1 2022
entrez: 16 2 2021
Statut: ppublish

Résumé

Major depressive disorder (MDD) is common in multiple sclerosis (MS) and its incidence rises before MS diagnosis. However, the causality and direction of this association remain unclear. The objective is to investigate the bidirectional relationship between MS and MDD using Mendelian randomization (MR). We selected genetic instruments associated with risk of MDD ( We found no effect of genetic liability to MDD on the odds of MS (OR = 1.07/doubling in odds, 95% CI = 0.90-1.28). Similarly, our findings did not support a causal effect of genetic liability to MS on MDD (OR = 1.00/doubling in odds, 95% CI = 0.99-1.01). Despite heterogeneity, sensitivity analyses indicated that bias from pleiotropy was unlikely. Conversely, genetic predisposition toward higher BMI increased the odds of MS (OR = 1.34/SD increase, 95% CI = 1.09-1.65) and MDD (OR = 1.08, 95% CI = 1.01-1.15). This study does not support a causal association between MDD genetic liability and MS susceptibility, and vice versa. Genetic evidence suggesting commonality of obesity to both conditions may partly explain the increased incidence of depression pre-MS diagnosis.

Sections du résumé

BACKGROUND
Major depressive disorder (MDD) is common in multiple sclerosis (MS) and its incidence rises before MS diagnosis. However, the causality and direction of this association remain unclear.
OBJECTIVE
The objective is to investigate the bidirectional relationship between MS and MDD using Mendelian randomization (MR).
METHODS
We selected genetic instruments associated with risk of MDD (
RESULTS
We found no effect of genetic liability to MDD on the odds of MS (OR = 1.07/doubling in odds, 95% CI = 0.90-1.28). Similarly, our findings did not support a causal effect of genetic liability to MS on MDD (OR = 1.00/doubling in odds, 95% CI = 0.99-1.01). Despite heterogeneity, sensitivity analyses indicated that bias from pleiotropy was unlikely. Conversely, genetic predisposition toward higher BMI increased the odds of MS (OR = 1.34/SD increase, 95% CI = 1.09-1.65) and MDD (OR = 1.08, 95% CI = 1.01-1.15).
CONCLUSION
This study does not support a causal association between MDD genetic liability and MS susceptibility, and vice versa. Genetic evidence suggesting commonality of obesity to both conditions may partly explain the increased incidence of depression pre-MS diagnosis.

Identifiants

pubmed: 33591230
doi: 10.1177/1352458521993075
pmc: PMC8364919
mid: NIHMS1724575
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2077-2084

Subventions

Organisme : NIMH NIH HHS
ID : K01 MH121582
Pays : United States

Références

J Neuroimmunol. 1991 Feb;31(2):147-53
pubmed: 1991821
Science. 2018 Jun 22;360(6395):
pubmed: 29930110
Neurology. 2018 Apr 10;90(15):e1316-e1323
pubmed: 29523642
Int J Epidemiol. 2019 Jun 1;48(3):728-742
pubmed: 30561657
Neurology. 2019 Apr 16;92(16):e1803-e1810
pubmed: 30894442
Genet Epidemiol. 2016 Nov;40(7):597-608
pubmed: 27625185
Science. 2019 Sep 27;365(6460):
pubmed: 31604244
Nature. 2015 Feb 12;518(7538):197-206
pubmed: 25673413
Genet Epidemiol. 2016 May;40(4):304-14
pubmed: 27061298
Mult Scler. 2005 Jun;11(3):328-37
pubmed: 15957516
Neurology. 2015 Dec 1;85(22):1972-9
pubmed: 26519542
Int J Epidemiol. 2019 Jun 1;48(3):834-848
pubmed: 30423117
Int J Epidemiol. 2015 Apr;44(2):512-25
pubmed: 26050253
Neurology. 2016 Apr 5;86(14):1279-1286
pubmed: 26962066
Nat Genet. 2018 May;50(5):693-698
pubmed: 29686387
Epidemiol Psychiatr Sci. 2019 Jun;28(3):333-342
pubmed: 29098977
Ital J Neurol Sci. 1998 Jun;19(3):171-5
pubmed: 10933472
Hum Mol Genet. 2014 Sep 15;23(R1):R89-98
pubmed: 25064373
Curr Neuropharmacol. 2016;14(7):732-42
pubmed: 27640518
BMC Med. 2013 Sep 12;11:200
pubmed: 24228900
Stat Med. 2008 Apr 15;27(8):1133-63
pubmed: 17886233
Stat Med. 2021 Nov 10;40(25):5434-5452
pubmed: 34338327
Gen Hosp Psychiatry. 2018 Jul - Aug;53:65-72
pubmed: 29929117
PLoS Med. 2016 Jun 28;13(6):e1002053
pubmed: 27351487
Nat Neurosci. 2019 Mar;22(3):343-352
pubmed: 30718901
PLoS One. 2010 Jun 25;5(6):e11296
pubmed: 20593013
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Neurol Genet. 2016 Aug 04;2(4):e87
pubmed: 27540591
PLoS Med. 2013;10(2):e1001383
pubmed: 23393431
Mult Scler. 2018 Jan;24(1):80-85
pubmed: 29307294
Eur J Epidemiol. 2018 Oct;33(10):947-952
pubmed: 30039250
Transl Psychiatry. 2018 Jan 10;8(1):9
pubmed: 29317602
Int J Biostat. 2016 Nov 1;12(2):
pubmed: 27092657
Mult Scler. 2016 Mar;22(3):347-53
pubmed: 26041803

Auteurs

Adil Harroud (A)

Department of Neurology, University of California San Francisco, San Francisco, CA, USA/Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.

Ruth Ann Marrie (RA)

Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada/Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.

Kathryn C Fitzgerald (KC)

Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Amber Salter (A)

Department of Biostatistics, Washington University in St. Louis, St. Louis, MO, USA.

Yi Lu (Y)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Mitulkumar Patel (M)

College of Pharmacy, University of Manitoba, Winnipeg, MB, Canada.

Kaarina Kowalec (K)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden/College of Pharmacy, University of Manitoba, Winnipeg, MB, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH